Advicenne

Advicenne has been committed to the development and commercialization of innovative therapies to address unmet medical needs in the field of nephrology. Our lead candidate drug, ADV7103, is currently in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria.